Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children

Environmental and Molecular Mutagenesis

Volumn 52, Issue 2, 2011, Pages 105-116

  Huen, Karen ^a   Barcellos, Lisa ^a   Beckman, Kenneth ^b   Rose, Sherri ^a   Eskenazi, Brenda ^a   Holland, Nina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Children; Functional genomics; Haplotype blocks; Indels; Oxidative stress; Pesticides

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; PESTICIDE;

ADULT; ARTICLE; CHILD; COHORT ANALYSIS; ENVIRONMENTAL EXPOSURE; ENZYME ASSAY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; FUNCTIONAL GENOMICS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MOTHER; OXIDATIVE STRESS; POPULATION GENETICS; PREGNANT WOMAN; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYLDIALKYLPHOSPHATASE; CHILD; COHORT STUDIES; ESTERASES; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; INDEL MUTATION; INFANT, NEWBORN; LINKAGE DISEQUILIBRIUM; LONGITUDINAL STUDIES; MEXICAN AMERICANS; MOTHERS; PESTICIDES; PHOSPHORIC ACID ESTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 79551614775     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20567     Document Type: Article

References (45)

1. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LSt, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Sestan N, State MW. 2005. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 310: 317-320.
2. Aviram M, Rosenblat M. 2004. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37: 1304-1316.
3. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD, haplotype maps. Bioinformatics 21: 263-265.
4. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57: 289-300.
5. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299: 1265-1276.
6. Borel C, Antonarakis SE. 2008. Functional genetic variation of human miRNAs and phenotypic consequences. Mamm Genome 19: 503-509.
7. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68: 1428-1436.
8. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111: 1403-1409.
9. Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. 2005. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol Biomarkers Prev 14: 731-734.
10. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49: 245-250.
11. Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. 2003. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 8: 1-12.
12. Costa LG, Cole TB, Vitalone A, Furlong CE. 2005a. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352(1-2): 37-47.
13. Costa LG, Vitalone A, Cole TB, Furlong CE. 2005b. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69: 541-550.
14. Deakin S, Leviev I, Brulhart-Meynet MC, James RW. 2003. Paraoxonase-1 promoter haplotypes and serum paraoxonase: A predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J 372: 643-649.
15. Deakin SP, James RW. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 107: 435-447.
16. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46: 1239-1247.
17. Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, Farrer LA. 2006. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 15: 77-85.
18. Eskenazi B, Bradman A, Gladstone E, Jaramillo S, Birch K, Holland N. 2003. CHAMACOS, a longitudinal birth cohort study: Lessons from the fields. J Childrens Healt 1: 3-27.
19. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16: 183-190.
20. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. 2002. The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
21. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11: 412-419.
22. Harley K, Eskenazi B, Block G. 2005. The association of time in the US, diet during pregnancy in low-income women of Mexican descent. Paediatr Perinat Epidemiol 19: 125-134.
23. Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, Beckman K, Eskenazi B. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 114: 985-991.
24. Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U. 2007. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 115: 2055-2064.
25. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. 2009. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402: 67-74.
26. Huen K, Harley K, Bradman A, Eskenazi B, Holland N. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol (in press).
27. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, et al. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 23: 1465-1471.
28. Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H. 2004. Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. Ann Hum Genet 68: 110-119.
29. Kondrashov AS, Rogozin IB. 2004. Context of deletions and insertions in human coding sequences. Hum Mutat 23: 177-185.
30. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, Saito S, Miller NE, Hattori H. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41: 1358-1363.
31. Landers JE, Shi L, Cho TJ, Glass JD, Shaw CE, Leigh PN, Diekstra F, Polak M, Rodriguez-Leyva I, Niemann S, Traynor BJ, McKenna-Yasek D, Sapp PC, Al-Chalabi A, Wills AM, Brown RHJr. 2008. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph Lateral Scler 9: 306-314.
32. Le Hir H, Nott A, Moore MJ. 2003. How introns influence and enhance eukaryotic gene expression. Trends Biochem Sci 28: 215-220.
33. Li HL, Liu DP, Liang CC. 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81: 766-779.
34. Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, Huang Y, Chen D, Xu X. 2005. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet Med 7: 58-63.
35. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507.
36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
37. Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, Vandeberg JL, Almasy L, Blangero J, Maccluer JW, Mahaney MC. 2009. Determinants of variation in human serum paraoxonase activity. Heredity 102: 147-154.
38. Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 205: 282-289.
39. Sanghera DK, Manzi S, Minster RL, Shaw P, Kao A, Bontempo F, Kamboh MI. 2008. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann Hum Genet 72: 72-81.
40. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, Hatzigeorgiou AG, Antonarakis SE. 2007. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 81: 405-413.
41. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D. 2007. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39: 605-613.
42. The International HapMap Consortium. 2003. The International HapMap Project. Nature 426: 789-796.
43. Xu Z, Taylor JA. 2009. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 37(Web Server issue): W600-W605.
44. Zintzaras E, Hadjigeorgiou GM. 2004. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. J Hum Genet 49: 474-481.
45. Zoghbi HY, Orr HT. 2000. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23: 217-247.